Loading organizations...

§ Venture Capital · New York City, NY, USA
Not-for-profit impact investment firm mobilizing capital to accelerate global health product development and access.
Global Health Investment Corporation is a not-for-profit impact investment firm based in New York that mobilizes private, public, and philanthropic capital to accelerate the development and commercialization of global health technologies. Operating as a tax-exempt 501(c)4 social welfare organization, the firm applies venture capital practices and blended finance structures to address high-burden infectious diseases and health security challenges in developing markets. The organization receives strategic financial support from prominent entities including the Bill & Melinda Gates Foundation and JP Morgan Chase to fund commercialization efforts and improve critical product access globally. Key leadership includes Chairman Labeeb M. Abboud, who has overseen investment operations since 2014, alongside Managing Director Michael Chang and Chief Investment Officer Vidya Vasudevan. Global Health Investment Corporation was formally established in 2012 with initial sponsorship and backing from the Bill & Melinda Gates Foundation.
Key people at Global Health Investment Corporation.
Global Health Investment Corporation (GHIC) is a nonprofit impact investment firm dedicated to catalyzing the development and commercialization of innovative technologies that improve global health and health equity, particularly in low- and middle-income countries. Its mission centers on investing in life sciences and healthcare companies that address infectious diseases, maternal and child health, and global health security, including pandemic preparedness. GHIC manages transformative funds such as the $108 million Global Health Investment Fund (GHIF), which has supported companies developing diagnostics, vaccines, and therapeutics for diseases like HIV/AIDS, malaria, tuberculosis, and cholera, delivering products to over 500 million people. Recently, GHIC expanded its focus to include global health security through a partnership with BARDA (Biomedical Advanced Research and Development Authority), investing in technologies to prevent and respond to public health emergencies[1][2][3].
Founded in 2010, GHIC was established to bridge the gap between public health needs and private capital by structuring innovative investment funds that generate both social impact and financial returns. Labeeb M. Abboud, the Chairman and CEO since 2014, has been instrumental in shaping GHIC’s strategy and expanding its mission to include global health security, leading partnerships with government and philanthropic stakeholders. GHIC’s evolution reflects a growing recognition of the importance of health security alongside traditional global health challenges, leveraging venture capital approaches to accelerate product development and accessibility[5].
GHIC rides the critical trend of integrating impact investing with global health innovation, addressing both long-standing infectious diseases and emergent health security threats like pandemics. The timing is pivotal given recent global experiences with COVID-19, which underscored the need for rapid development and deployment of diagnostics, vaccines, and therapeutics. Market forces such as increased government funding for health security, growing private sector interest in social impact, and advances in biotechnology favor GHIC’s model. By bridging public health priorities with entrepreneurial innovation, GHIC influences the broader ecosystem by de-risking investments in neglected diseases and health security, fostering a pipeline of scalable health technologies that improve equity worldwide[1][2][6][7].
Looking ahead, GHIC is poised to expand its global health security portfolio, leveraging up to $500 million in BARDA funding over a decade to support cutting-edge medical countermeasures. Trends shaping its journey include advances in vaccine design, biomanufacturing technologies, and diagnostics, alongside increasing global emphasis on pandemic preparedness. GHIC’s influence is likely to grow as it continues to demonstrate that impact-driven investment can accelerate health innovation while delivering sustainable financial returns. Its evolving strategy positions it at the nexus of global health equity and security, making it a key player in shaping a healthier, safer world through entrepreneurial solutions[2][6][7].
In sum, GHIC exemplifies how mission-driven investment can transform global health challenges into opportunities for innovation and impact, bridging sectors and capital to protect and improve lives worldwide.
Key people at Global Health Investment Corporation.
Global Health Investment Corporation has 5 tracked investments across 4 companies. The latest tracked deal is $20.0M Series A in Prenosis in January 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 29, 2026 | Prenosis | $20.0M Series A | PACE Healthcare Capital | Carle, Illinois Department OF Commerce & Economic Opportunity, LabCorp Venture Fund, UCI Health, UC Investments, UCI Health Ventures |
| Jan 27, 2026 | Antheia | $24.0M Series C Extension | Jeff Karras, Athos | — |
| Jan 1, 2025 | Micron Biomedical | $16.0M Series A | J2 Ventures, Global Health Investment Corporation | — |
| May 1, 2024 | Vaxess Technologies | $12.0M Series U | — | The Engine, Vsquared Ventures, Engine Ventures, Mission BioCapital, RA Capital Management |
| Sep 1, 2023 | Vaxess Technologies | $9.0M Series U | — | The Engine, ULU Ventures, Vsquared Ventures, RA Capital Management |